Physician profile

Matthew Griffith

Acute Care (Nurse Practitioner) · Nashville, TN

NPI 1295518579

$196.41

in general payments reported to CMS, 2019-2025

6 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$196.41

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Electromed, INC. $69.72 2023-2024 Smartvest
Grifols USA, LLC $39.75 2023-2024 Prolastin-C Liquid
Boehringer Ingelheim Pharmaceuticals, INC. $30.19 2023 Spiriva Respimat, Stiolto Respimat
Takeda Pharmaceuticals U.S.A., INC. $26.62 2024 Hyqvia
Merck Sharp & Dohme LLC $15.44 2023 Zerbaxa, Recarbrio
Glaxosmithkline, LLC. $14.69 2024 Arexvy, Trelegy Ellipta

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Matthew Griffith

$196.41

in general payments reported 2019-2025

Years
2023-2024
Top company
Electromed, INC.

https://glasscript.com/doctor/11489251/matthew-griffith

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.